Company
COIL +0.82%Coiled Therapeutics plc
Market Cap: £41.6 Million
GBP as of Aug 2, 2026 | US$55.9 Million
$COIL +0.82% $COIL United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyCompany Description
Coiled Therapeutics plc is a clinical-stage biotechnology company focused on developing precision oncology therapies for patients with hard-to-treat cancers. The company’s core activity is the discovery and development of next-generation medicines targeting validated cancer pathways, with an emphasis on solid tumours that have progressed after standard treatments. Its lead programme, AO-252, is a first-in-class, orally administered, brain-penetrant inhibitor of the TACC3 protein, currently being evaluated in a Phase I clinical trial in the United States for advanced solid tumours, including ovarian and prostate cancer. Coiled Therapeutics also maintains a STAT-6 siRNA programme addressing immunology-related indications such as asthma, fibrosis, eczema, and allergic disease, broadening its reach across oncology and immune-mediated conditions. Operating within the biotechnology segment of the healthcare sector, the company serves global pharmaceutical and clinical research markets by advancing novel small-molecule and RNA-based therapeutics designed to improve treatment options and clinical outcomes for patients. Coiled Therapeutics plc is headquartered in London, United Kingdom.
Coiled Therapeutics plc Market Capitalization Over Time
View HistoryEvolution of Coiled Therapeutics plc market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Coiled Therapeutics plc is a clinical-stage biotechnology company focused on developing precision oncology therapies for patients with hard-to-treat cancers. The company’s core activity is the discovery and development of next-generation medicines targeting validated cancer pathways, with an emphasis on solid tumours that have progressed after standard treatments. Its lead programme, AO-252, is a first-in-class, orally administered, brain-penetrant inhibitor of the TACC3 protein, currently being evaluated in a Phase I clinical trial in the United States for advanced solid tumours, including ovarian and prostate cancer. Coiled Therapeutics also maintains a STAT-6 siRNA programme addressing immunology-related indications such as asthma, fibrosis, eczema, and allergic disease, broadening its reach across oncology and immune-mediated conditions. Operating within the biotechnology segment of the healthcare sector, the company serves global pharmaceutical and clinical research markets by advancing novel small-molecule and RNA-based therapeutics designed to improve treatment options and clinical outcomes for patients. Coiled Therapeutics plc is headquartered in London, United Kingdom.
Financials
| Last Financial Reports Date | Dec. 31, 2025 |
| Revenue TTM | £0 |
| EBITDA | £0 |
| Gross Profit TTM | £0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Coiled Therapeutics plc main stocks and indexes inclusions.
$COILFTSE AIM All-Share